Welcome to the first issue of this letter. As many of you know, I am Dr. Ojobor. I have had the pleasure of connecting with many of you personally, and I think it is important for you to hear about the latest science directly from the company’s leadership. In each issue, I take one piece of microbiome science, the kind that usually stays locked inside journals and conference rooms, and translate it into something you can use with the patient sitting across from you. I read this literature for a living. You see patients for a living. This letter exists to close the distance between those two jobs.

I want to start with a story I have told in training rooms many times, because it captures why Vitract exists. A woman in her late forties, tired in a way sleep would not fix. Hot flashes, brain fog, weight settling in new places, sleep shattering at 3 a.m. Her hormone panel came back unremarkably for her age, and she was told that this was simply menopause and she should ride it out.

The panel was not wrong. It was incomplete. It measured what her ovaries were producing but said nothing about the organ deciding how much of that estrogen she actually got to keep, how her brain was being signalled, or why her sleep kept breaking at the same hour.

That organ is her gut, and it is precisely the organ most clinicians were never trained to read.

Below are four questions the microbiome answers about a symptomatic woman that no hormone panel can. Hold these in mind, and you will start to see a seemingly scattered symptom list collapsing into mechanism.

Question 1: How much estrogen is she actually keeping?

After estrogen has done its work, the liver conjugates it, tags it for disposal, and sends it into the intestine through bile. That should be the end of the story. But it is not. A community of gut bacteria carrying the enzyme beta-glucuronidase snips that tag off and returns estrogen to circulation. This is the estrobolome, and it means every woman runs an internal estrogen recycling program whose net output is set by her microbes, not her ovaries.

In a younger woman with endometriosis, fibroids, or heavy painful cycles, an overactive estrobolome, elevated Clostridia and Ruminococcaceae associated with high beta-glucuronidase activity, keeps reclaiming estrogen and feeding the fire. In a perimenopausal woman, the opposite dominates. Recycling capacity fades exactly when ovarian output is falling, and she loses even the estrogen she has left. This is why two women with near-identical estradiol on lab reports can have entirely different menopauses, and why the panel so often fails to predict the suffering. When you see estrogen-dependent pathology, or symptoms out of proportion to bloodwork, look at the estrobolome.

Question 2: Will soy actually help her?

The answer is written in her microbiome before she eats a single edamame pod. The benefit of soy for vasomotor symptoms does not come from soy. It comes from equol, a metabolite produced only by women carrying species such as Slackia isoflavoniconvertens and Adlercreutzia equolifaciens. Roughly a third to a half of women host them. The rest can eat tofu three nights a week and make almost none, then conclude their bodies are broken when nothing improves.

This is the cleanest example I know of a general recommendation that is only conditionally true, and that condition is dictated by her gut microbiome. Once you can distinguish a producer from a non-producer, you stop asking a woman’s diet to do something her microbiome cannot, and you redirect that effort somewhere it will pay off. That alone changes the advice you give.

Question 3: Is her barrier holding as estrogen falls?

Estrogen helps keep the intestinal barrier sealed. As it declines, the lining thins, inflammatory fragments like lipopolysaccharide begin leaking into circulation, and that low-grade inflammation is a key part of why perimenopausal women feel puffy, foggy, and unwell. The counterforce is butyrate, produced by species such as Faecalibacterium prausnitzii and Roseburia intestinalis, which feeds colonocytes and tightens the barrier back up. Beside them, Akkermansia muciniphila keeps the mucus layer renewing, provided it is not overrun by aggressive mucus degraders like Ruminococcus gnavus.

When butyrate producers are thinning at the same time estrogen is leaving, you are looking at two withdrawals at once. That is not a situation you shrug and ride out. You are looking at a microbiome dysbiosis problem with a measurable target, and it is one of the most tractable findings on any report you will read.

Question 4: Why is she anxious and awake at 3 a.m.?

Most of the body’s serotonin is manufactured in the gut, and gut bacteria influence how much tryptophan moves toward serotonin versus the kynurenine pathway in the brain. A second group, including Lactobacillus brevis and Bifidobacterium dentium, produces GABA, the same quieting system anti-anxiety medications act on. Estrogen normally props up both serotonin and GABA tone. In perimenopause that support is withdrawn at the very moment the gut community is often at its least stable, and the barrier leak from question three nudges cortisol upward at the wrong hour. The result is a woman snapping awake in the dark with her heart going, being told it is just menopause.

This is a signalling shortage, one that can be measured and rebuilt. Framing it that way, out loud, is itself an intervention.

What does this mean for your practice?

Notice what these four questions share. In each one, a woman had been handed reassurance when there was a mechanism sitting right there, unread. Her estrogen recycling, her response to soy, her leaking barrier, her shattered sleep. All traceable, and much of it modifiable.

We cannot give her back the estrogen levels she had at age thirty. But we can change what her gut does with the estrogen she has, and the microbiome is the one part of her hormonal life that stays open to change at fifty, at sixty, at seventy.

If a case on your desk right now looks like the woman in this letter, I want to hear about it. The best future issues of this newsletter will come from your clinic, not my desk.

Until then, keep reading the gut. It has been talking the whole time.

Chidozie

Co-founder & CSO, Vitract